January 19, 2022
Via: FiercePharma64x Bio, a fledgling synthetic cell and gene therapy manufacturer, brought in $55 million in a series A round of fundraising. The company, which has about 10 employees and was founded in 2020 out of the Harvard Department of Genetics, […]
July 11, 2024
July 11, 2024
July 19, 2024